IL-17 was elevated in our model, and because it is an emerging therapeutic target for cancer metastasis and arthritis [20-26], we tested if neutralizing IL-17 will be an effective therapy against the development of secondary metastasis in our arthritic model. The gene discussed is IL17A; the disease is arthritic joint disease.